Jennifer Geremia
MSPAS, PA-C
Introduction
Location : Cranston, RI, USA
Specialty : MASLD
BIO
Jennifer Geremia is a board-certified Physician Assistant specializing in gastroenterology and advanced endoscopy at Brigham and Women's Hospital in Boston, Massachusetts. With over 14 years of experience, she provides comprehensive care across a spectrum of gastrointestinal diseases.
Jennifer earned her Master of Science in Physician Assistant Studies from the Massachusetts College of Pharmacy and Health Sciences. She is actively involved in academia, serving as clinical faculty at the Massachusetts College of Pharmacy and Health Sciences PA Program, and as an adjunct professor at the University of New England PA Program and the Massachusetts General Hospital School of Health Professions PA Program.
Committed to advancing the field, Jennifer contributes to professional organizations such as the Gastroenterology and Hepatology Advanced Practice Providers National Organization and the American Society for Gastrointestinal Endoscopy.
Highlighted Events
Glide Conference
April 26 @ 12:00 pm - 12:00 pm EST
The Greater Long Island Digestive Education (GLIDE) Conference will deliver focused educational updates highlighting clinically relevant advances in t..
GHAPP Regional
July 31 @ 12:00 pm - 12:00 pm EST
Speakers: Jennifer Geremia, PA-C Brigham and Women's Hospital Boston, MA Miu Lai (Milly) Ng, FNP-BC, MPH, MSN, RN Tufts Medical Cen..
GHAPP Eighth Annual Conference
September 04 @ 12:00 pm - September 06 @ 12:00 pm MDT
About the 2025 GHAPP Conference The GHAPP conference is the only conference specifically designed by advanced practice providers (APPs) for the pur..
MASH Content Featuring Geremia's, MSPAS, PA-C
Clinical Deep Dive: Unlocking the Treatment Potential of Rezdiffra
This educational discussion dives into Rezdiffra, the first and only FDA-approved therapy for non-cirrhotic metabolic-associated steatohepatitis (MASH) with moderate to advanced fibrosis. The talk provides a clinical deep dive into the progression of MASH and fibrosis, highlighting the risks of untreated disease and the importance of early intervention. A key focus is the thyroid hormone receptor beta mechanism, explaining how Rezdiffra directly targets liver-specific pathways to reduce hepatic fat accumulation and fibrosis. Additionally, the discussion covers the rigorous FDA approval process and dual efficacy endpoints, detailing how Rezdiffra achieved significant fibrosis improvement and steatohepatitis resolution in the MAESTRO-NASH trial. The session also provides practical insights into patient access, prescribing considerations, and managing common side effects. With over 2,000 patients studied, Rezdiffra has demonstrated a strong safety profile and offers a once-daily oral treatment option that represents a major advancement in MASH management. This discussion is essential for gastroenterologists, hepatologists, and endocrinologists managing patients with MASH, as well as primary care providers and cardiologists who play a role in identifying at-risk individuals. If you are a healthcare professional looking to stay updated on the latest MASH research and treatment strategies, this session provides the insights you need.
Watch Now
Management of Life Style Modification
This video focuses on the comprehensive management of patients with metabolic-associated steatohepatitis (MASH), emphasizing lifestyle modifications, dietary adjustments, and exercise strategies. Key topics include the importance of addressing risk factors like diet, exercise habits, and alcohol intake, as well as referrals to medically supervised weight loss clinics or bariatric surgery for advanced cases. The speaker highlights the benefits of the Mediterranean diet, intermittent fasting, and avoiding ultra-processed foods while discussing the role of resistance training to combat sarcopenia and maintain muscle mass. Practical advice and tailored recommendations ensure a holistic approach to managing MASH and improving patient outcomes.
Watch Now
Third Step of Life Style Management
This video provides a comprehensive overview of emerging pharmacologic treatments for metabolic-associated steatohepatitis (MASH) and their tailored applications based on patient profiles. Topics include FDA-approved therapies, drugs in advanced clinical trials (such as semaglutide and lanifibranor), and the potential for combination treatments targeting both steatohepatitis and fibrosis. The speaker emphasizes the importance of patient-specific approaches considering metabolic profiles, obesity, and diabetes status, alongside lifestyle interventions. Additionally, the video discusses the evolving interdisciplinary care model and highlights the exciting progress in non-invasive testing and treatment advancements for F2-F3 fibrosis.
Watch Now
